Background Non-AIDS-defining cancers (NADCs) are now becoming a rising cause of
morbidity among people living with HIV (PLHIV) in the highly active antiretroviral therapy …

Background The benefits of direct-acting antivirals towards the elimination of hepatitis C
virus (HCV) in people living with HIV are decreased when individuals are reinfected with …

COVID-19 has affected people of all ages, in different ways. But beyond the impacts of the
virus itself, some of the narratives about different age groups have exposed a deep and …

The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment
and care for key populations outline a public health response for five key populations (men …

Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but
most patients can now expect to achieve a sustained virological response (SVR). With direct …

Acute hepatitis C virus (HCV) infection is a global health concern with substantial
geographical variation in the incidence rate. People who have received unsafe medical …

Abstract The Infectious Diseases Society of America and the American Association for the
Study of Liver Diseases have collaboratively developed evidence-based guidance …

The phases of hepatitis C elimination: achieving WHO elimination targets The phases of
hepatitis C elimination: achieving WHO elimination targets Lancet Gastroenterol Hepatol …

Background Global data on the treatment rate with direct‐acting antivirals (DAAs) for chronic
hepatitis C (CHC) are sparse. We aimed to evaluate the CHC treatment rate and barriers to …

Abstract Background & Aims Detecting hepatitis C virus (HCV) reinfection among key
populations helps prevent ongoing transmission. This systematic review aims to determine …